Oncoinvent ASA Announces Second Half 2025 Results with Positive Radspherin Trial Data and Corporate Milestones

on

Oncoinvent reported positive final data from Phase 1 Trial of Radspherin to treat ovarian cancer and published results in Gynecologic Oncology1

The company presented final safety and efficacy results from the Phase 1/2a trial of Radspherin for colorectal cancer at the 15th PSOGI International Congress on Peritoneal Surface Malignancies1

Oncoinvent completed a merger with BerGenBio and successfully uplisted to the Oslo Stock Exchange1

The company raised NOK 130 million in equity and appointed Dr Ramzi Amri as Chief Financial Officer1

Data from trials in ovarian and colorectal cancers showed an excellent safety profile and meaningful signals of efficacy3

Interim data from an ongoing Phase 2 randomized controlled trial in ovarian cancer is expected in 20263

In January 2026, Oncoinvent included four additional sites in its Phase 2 trial1

In February 2026, the company presented positive 24-month follow-up data from the Phase 1 ovarian cancer trial at the 27th Congress of the European Society of Gynecological Oncology1

Operating loss for the second half of 2025 was NOK 106 million, driven primarily by clinical activity and merger-related accounting effects5

Cash balance at period end was NOK 178 million5

Sources:

1. https://www.morningstar.com/news/pr-newswire/20260226cg96504/oncoinvent-asa-second-half-2025-results

3. https://live.euronext.com/en/products/equities/company-news/2026-02-26-oncoinvent-asa-second-half-2025-results

5. https://www.marketscreener.com/news/oncoinvent-second-half-of-2025-report-and-presentation-presentation-ce7e5cd8dd8cf121